This study phase involves relatively small studies and has a goal to explore therapeutic efficacy. Answer Choices: Non-Clinical Studies, Phase I, Phase II, Phase III, Phase IV
What is Phase II?
The main characteristic of this study design is that each participant acts as their own control. Answer Choices: Parallel Group Design, Crossover Design, Factorial Design, Group Sequential Design
What is a Crossover Design?
According to the principles of ICH GCP, this is the most important consideration when conducting a clinical trial. Answer choices: Protecting the rights, safety, and well-being of trial participants; Following the proper regulations and guidelines; Having proper recruiting/retention practices
What is "protecting the rights, safety and well-being of trial participants"?
Excluding participants from the data analysis based on your knowledge of their study outcome is an example of this type of study bias. Answer Choices: Operational, Statistical, Design, Compliance
What is Statistical bias? (Note- Design and Compliance options are "distractors")
When a protocol deviation occurs, the FIRST priority is to:
Answer choices: Notify the IRB, Assess impact on participant safety and data integrity, Retrain site staff, Document in the Case Report Form
What is assess impact on participant safety and data integrity?
These items regarding your study population are important for both the trial planning and trial execution. Failure to meet expectations of these can affect the duration of the trial and have financial implications. Answer Choices (select all that apply): recruitment predictions, actual recruitment, participant retention
What are: (all of the above) recruitment predictions, actual recruitment, and participant retention.
Amendments involving changes to IRB approved protocols do NOT need prior IRB approval in this instance. Answer Choices: changes that impact the immediate health/well-being of the participant; changes involve the ICF only; the sponsor tells the investigator to implement the changes immediately
What is "when the changes impact the immediate health/well-being of the participant"?
This type of Analysis Set includes all randomized participants, whether or not they received investigational product or completed the study without major deviations/violations. Answer Choices: Intention-to-Treat , Per-Protocol Analysis , Interim Analysis
What is an Intention-to-Treat (ITT)? (Note- Interim Analysis was a distractor)
At the final study visit, the CRC discovered a participant has not been taking the IP correctly. The pill counts throughout the study appeared to show the subject in compliance. The CRC knows he/she should take this action first in order to begin to resolve the issue. Answer choices: report the noncompliance to the sponsor; document the noncompliance in the CRF; chastise the participant for their noncompliance; have the participant re-enroll in the study and disregard all previous data for that participant
What is "document the available information regarding the noncompliance in the CRF".
This randomization type is the simplest method, allowing for all participants to have an equal chance of receiving treatment but leading to potential issues in equality across the comparison groups. Answer Choices: Unrestricted, Block, Central, Stratified, Dynamic
What is Unrestricted randomization?
<<< Daily Double >>> A participant whose speaks Spanish as a first language comes to the site for screening with her bilingual daughter. The CRC only has ICFs written in English available. The CRC's next action is to do this. Answer Choices: use the daughter as a translator; find a non-biased translator; request a Spanish language ICF from the sponsor; document the subject as a screen failure
What is: request a Spanish language ICF from the sponsor to provide for the subject.
Daily Double: When the participant returns for screening after the Spanish language ICF is available, what else will the CRC need to do to complete the informed consent process?
During the informed consent process, the ICF will need to be signed by ______________ and ___________.
Who are: the participant and the person obtaining the consent